Nektar Therapeutics (NKTR):企業の財務・戦略的SWOT分析

◆英語タイトル:Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH4344FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Nektar Therapeutics (NKTR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of wide range of molecules including wide classes of drugs targeting numerous disease areas. The company’s products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

Feb 26,2021: Nektar Therapeutics reports fourth quarter and year-end 2020 financial results
Feb 18,2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021
Jan 05,2021: Nektar appoints Dr. Brian Kotzin as interim chief medical officer and head of development
Nov 05,2020: Nektar Therapeutics reports third quarter 2020 financial results
Sep 28,2020: Nektar Therapeutics : Departure of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Nektar Therapeutics – Key Facts
Nektar Therapeutics – Key Employees
Nektar Therapeutics – Key Employee Biographies
Nektar Therapeutics – Major Products and Services
Nektar Therapeutics – History
Nektar Therapeutics – Company Statement
Nektar Therapeutics – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Nektar Therapeutics – Business Description
Geographical Segment: Rest of World
Performance
Geographical Segment: United States
Performance
Nektar Therapeutics – Corporate Strategy
Nektar Therapeutics – SWOT Analysis
SWOT Analysis – Overview
Nektar Therapeutics – Strengths
Nektar Therapeutics – Weaknesses
Nektar Therapeutics – Opportunities
Nektar Therapeutics – Threats
Nektar Therapeutics – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Nektar Therapeutics, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 26, 2021: Nektar Therapeutics reports fourth quarter and year-end 2020 financial results
Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021
Jan 05, 2021: Nektar appoints Dr. Brian Kotzin as interim chief medical officer and head of development
Nov 05, 2020: Nektar Therapeutics reports third quarter 2020 financial results
Sep 28, 2020: Nektar Therapeutics : Departure of Directors
Aug 06, 2020: Nektar Therapeutics reports second quarter 2020 financial results
May 07, 2020: Nektar Therapeutics reports first quarter 2020 financial results
May 07, 2020: Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
Feb 27, 2020: Nektar Therapeutics reports fourth quarter and year-end 2019 financial results
Feb 27, 2020: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Nektar Therapeutics, Key Facts
Nektar Therapeutics, Key Employees
Nektar Therapeutics, Key Employee Biographies
Nektar Therapeutics, Major Products and Services
Nektar Therapeutics, History
Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries
Nektar Therapeutics, Key Competitors
Nektar Therapeutics, Ratios based on current share price
Nektar Therapeutics, Annual Ratios
Nektar Therapeutics, Annual Ratios (Cont...1)
Nektar Therapeutics, Annual Ratios (Cont...2)
Nektar Therapeutics, Interim Ratios
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Nektar Therapeutics, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Nektar Therapeutics (NKTR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aurora Energy Pty Ltd:企業の戦略的SWOT分析
    Aurora Energy Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Hey-Song Corporation:企業の戦略・SWOT・財務情報
    Hey-Song Corporation - Strategy, SWOT and Corporate Finance Report Summary Hey-Song Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Surge Energy Inc (SGY):石油・ガス:M&Aディール及び事業提携情報
    Summary Surge Energy Inc (Surge) is an oil and gas company that offers acquisitions, exploration and production of crude oil and natural gas reserves. The company provides risk management and risk development drilling services. Its oil and natural gas producing properties include Shaunavon and Dodsl …
  • Swift Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company offers products such as 2S DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • DURECT Corp (DRRX):医療機器:M&Aディール及び事業提携情報
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • Yakult Honsha Co Ltd (2267):企業の財務・戦略的SWOT分析
    Yakult Honsha Co Ltd (2267) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • KSK Group Berhad:企業の戦略・SWOT・財務情報
    KSK Group Berhad - Strategy, SWOT and Corporate Finance Report Summary KSK Group Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Premier Foods plc (PFD):企業の財務・戦略的SWOT分析
    Premier Foods plc (PFD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • InteRNA Technologies BV:製薬・医療:M&Aディール及び事業提携情報
    Summary InteRNA Technologies BV (InteRNA) is a biotechnology company that develops RNA therapeutics for the treatment of cancer. The company develops technologies in biomedical research translating miRNA sequence fields. Its drug development programs offers developing miRNA-based therapeutics that c …
  • Commonwealth Bank of Australia:戦略・SWOT・企業財務分析
    Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report Summary Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析
    Summary Royal DSM NV (DSM) is a life sciences and materials sciences company, which focuses on health, nutrition and materials sectors. The company offers a wide range of products such as anti-invectives, polyesters, vitamins and other ingredients, performance materials to diverse end markets. It pr …
  • Engepack Embalagens Sa:企業の戦略・SWOT・財務分析
    Engepack Embalagens Sa - Strategy, SWOT and Corporate Finance Report Summary Engepack Embalagens Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • RTL Group S.A. (RTL):企業の財務・戦略的SWOT分析
    RTL Group S.A. (RTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Central Alabama Electric Cooperative Inc:企業の戦略的SWOT分析
    Central Alabama Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Delek US Holdings, Inc.:企業のM&A・事業提携・投資動向
    Delek US Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Delek US Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. Its pipeline products include Leronlimab (PRO 140), a ful …
  • Principal Financial Group Inc.:企業のM&A・事業提携・投資動向
    Principal Financial Group Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Principal Financial Group Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Herman Miller, Inc.:企業の戦略・SWOT・財務分析
    Herman Miller, Inc. - Strategy, SWOT and Corporate Finance Report Summary Herman Miller, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bonjour Holdings Limited:企業の戦略・SWOT・財務情報
    Bonjour Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bonjour Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tessa Therapeutics Pte Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Tessa Therapeutics Pte Ltd (Tessa Therapeutics) is a clinical-stage biotechnology company that develops and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response to identify and exterminate cancer cells. The company provides products for various c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆